<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00907296</url>
  </required_header>
  <id_info>
    <org_study_id>20062017</org_study_id>
    <secondary_id>2008-008392-34</secondary_id>
    <nct_id>NCT00907296</nct_id>
  </id_info>
  <brief_title>Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing</brief_title>
  <acronym>STARTT</acronym>
  <official_title>A Multi-center, Randomized, Double Blind, Placebo-controlled Study of AMG 785 in Skeletally Mature Adults With a Fresh Unilateral Tibial Diaphyseal Fracture Status Post Definitive Fracture Fixation With an Intramedullary Nail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate the effect of romosozumab compared with
      placebo on time to radiographic healing of fresh tibial diaphyseal fractures (fractures in
      the midsection of the shinbone).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2, 2009</start_date>
  <completion_date type="Actual">May 10, 2013</completion_date>
  <primary_completion_date type="Actual">March 6, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Radiographic Healing</measure>
    <time_frame>52 weeks</time_frame>
    <description>Time to radiographic healing was defined as the time from intramedullary (IM) nailing to the first occurrence of bridging of 3 out of 4 cortices. Radiographic fracture healing was determined by a panel of independent reviewers (orthopedic/trauma surgeons and radiologists) blinded to treatment.
The cumulative incidence function (CIF) method was used to estimate the median time to radiographic healing and the confidence intervals. Unplanned revision surgery to promote healing was considered a competing risk in CIF estimate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Week 8 in Short Form (36) Health Survey Physical Functioning Domain</measure>
    <time_frame>Week 8 and weeks 12, 16, 20, 24, 36, and 52</time_frame>
    <description>The Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2, is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical functioning domain includes 10 questions that assess limitations in physical activities because of health problems.
Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. The range of SF-36 physical functioning is 14.94 - 57.03. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement in physical functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Unplanned Revision Surgeries</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Healing</measure>
    <time_frame>52 weeks</time_frame>
    <description>Time to clinical healing was defined as the time from the IM nailing surgery date to the first date that both the score for ability to bear weight on the fractured limb and the score for absence of pain at the fracture site were equal to 6.
The score for the ability to bear weight on the fractured limb was based on the ability to stand on affected leg without assistive device and the ability to walk without assistive device. The score ranges from 0 (unable to bear full body weight on the fractured limb) to 6 (able to bear full body weight on the fractured limb). Absence of pain at the fracture site was based on the absence of pain at the fracture site when applying direct pressure to the fracture site and applying a stress to the fracture site. The score ranges from 0 (pain without palpation at fracture site) to 6 (total absence of pain at fracture site).
Time to clinical healing was estimated using CIF; unplanned revision surgery was considered a competing risk in CIF estimate.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">402</enrollment>
  <condition>Fracture Healing</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received subcutaneous injections of matching placebo on day 1 and at weeks 2, 6, and 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Romosozumab 70 mg: 2 Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Romosozumab 70 mg: 3 Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Romosozumab 70 mg: 4 Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Romosozumab 140 mg: 2 Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Romosozumab 140 mg: 3 Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Romosozumab 140 mg: 4 Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Romosozumab 210 mg: 2 Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Romosozumab 210 mg: 3 Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Romosozumab 210 mg: 4 Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Romosozumab</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>Romosozumab 140 mg: 2 Doses</arm_group_label>
    <arm_group_label>Romosozumab 140 mg: 3 Doses</arm_group_label>
    <arm_group_label>Romosozumab 140 mg: 4 Doses</arm_group_label>
    <arm_group_label>Romosozumab 210 mg: 2 Doses</arm_group_label>
    <arm_group_label>Romosozumab 210 mg: 3 Doses</arm_group_label>
    <arm_group_label>Romosozumab 210 mg: 4 Doses</arm_group_label>
    <arm_group_label>Romosozumab 70 mg: 2 Doses</arm_group_label>
    <arm_group_label>Romosozumab 70 mg: 3 Doses</arm_group_label>
    <arm_group_label>Romosozumab 70 mg: 4 Doses</arm_group_label>
    <other_name>AMG 785</other_name>
    <other_name>Evenity</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Skeletally mature adults, age 18 to 85 years with radiographically closed growth
             plates

          -  Fresh unilateral closed or Gustilo type I or type II open tibial fracture

          -  Definitive fracture fixation with reamed (closed and open fractures) or unreamed (open
             fractures only) intramedullary nailing

        Exclusion Criteria:

          -  Major polytrauma or significant axial trauma

          -  Associated lower extremity fracture that will delay subject's ability to bear weight
             beyond the normal time expected for a tibial shaft fracture

          -  Use of bone grafts at the time of fracture fixation

          -  Pathological fracture or metabolic or bone disease

          -  History of symptomatic spinal stenosis or facial nerve paralysis

          -  Malignancy within the last 5 years

          -  Evidence of the following (currently or within the past 5 years): elevated
             transaminases, significantly impaired renal function, current hyper- or hypocalcaemia

          -  Use of agents affecting bone metabolism

          -  Subject refuses to use appropriate methods of contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <zip>84070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Blagoevgrad</city>
        <zip>2700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruse</city>
        <zip>7000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Red Deer</city>
        <state>Alberta</state>
        <zip>T4N 6V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>L1S 2J5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 7C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 1R6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N9A 1E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>KÃ¸benhavn NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ã…rhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tallinn</city>
        <zip>11312</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tartu</city>
        <zip>50410</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris Cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mannheim</city>
        <zip>68165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>14561</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Patra</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1081</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <zip>575 002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411 005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302 022</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <zip>625 020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gandhinagar</city>
        <zip>382 428</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mangalore</city>
        <zip>575 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashik</city>
        <zip>422 009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma (RM)</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liepaja</city>
        <zip>3400</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <zip>1004</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <zip>1005</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valmiera</city>
        <zip>4201</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaunas</city>
        <zip>44320</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vilnius</city>
        <zip>04130</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo LeÃ³n</state>
        <zip>64040</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Christchurch</city>
        <zip>8022</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tauranga</city>
        <zip>3143</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kongsvinger</city>
        <zip>2226</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bytom</city>
        <zip>41-902</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>30-901</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>KrakÃ³w</city>
        <zip>31-826</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-718</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <zip>014461</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>050098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>115280</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>117292</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>127299</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>129327</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <zip>833 05</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nitra</city>
        <zip>950 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Piestany</city>
        <zip>921 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newcastle</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stanmore</city>
        <zip>HA7 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 21, 2009</study_first_submitted>
  <study_first_submitted_qc>May 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2009</study_first_posted>
  <results_first_submitted>April 10, 2019</results_first_submitted>
  <results_first_submitted_qc>April 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 1, 2019</results_first_posted>
  <disposition_first_submitted>May 22, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>May 22, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 23, 2013</disposition_first_posted>
  <last_update_submitted>April 10, 2019</last_update_submitted>
  <last_update_submitted_qc>April 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fracture Healing</keyword>
  <keyword>Tibial Diaphyseal Fracture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 66 centers in Europe, India, North America, Australia, New Zealand, Hong Kong, and Mexico. Participants were enrolled from 02 September 2009 to 19 September 2011.</recruitment_details>
      <pre_assignment_details>Participants were randomized 1:1:1:1:1:1:1:1:1:3 to 1 of 9 romosozumab treatment groups or placebo. Randomization followed surgery and was stratified by type of fracture and definitive fracture fixation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received subcutaneous injections of matching placebo on day 1 and at weeks 2, 6, and 12.</description>
        </group>
        <group group_id="P2">
          <title>Romosozumab 70 mg: 2 Doses</title>
          <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
        </group>
        <group group_id="P3">
          <title>Romosozumab 70 mg: 3 Doses</title>
          <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
        </group>
        <group group_id="P4">
          <title>Romosozumab 70 mg: 4 Doses</title>
          <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
        </group>
        <group group_id="P5">
          <title>Romosozumab 140 mg: 2 Doses</title>
          <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
        </group>
        <group group_id="P6">
          <title>Romosozumab 140 mg: 3 Doses</title>
          <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
        </group>
        <group group_id="P7">
          <title>Romosozumab 140 mg: 4 Doses</title>
          <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
        </group>
        <group group_id="P8">
          <title>Romosozumab 210 mg: 2 Doses</title>
          <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
        </group>
        <group group_id="P9">
          <title>Romosozumab 210 mg: 3 Doses</title>
          <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
        </group>
        <group group_id="P10">
          <title>Romosozumab 210 mg: 4 Doses</title>
          <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="33"/>
                <participants group_id="P5" count="33"/>
                <participants group_id="P6" count="33"/>
                <participants group_id="P7" count="33"/>
                <participants group_id="P8" count="33"/>
                <participants group_id="P9" count="31"/>
                <participants group_id="P10" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="32"/>
                <participants group_id="P5" count="33"/>
                <participants group_id="P6" count="32"/>
                <participants group_id="P7" count="31"/>
                <participants group_id="P8" count="32"/>
                <participants group_id="P9" count="30"/>
                <participants group_id="P10" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="29"/>
                <participants group_id="P5" count="32"/>
                <participants group_id="P6" count="24"/>
                <participants group_id="P7" count="27"/>
                <participants group_id="P8" count="26"/>
                <participants group_id="P9" count="27"/>
                <participants group_id="P10" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligibility Determined</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received subcutaneous injections of matching placebo on day 1 and at weeks 2, 6, and 12.</description>
        </group>
        <group group_id="B2">
          <title>Romosozumab 70 mg: 2 Doses</title>
          <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
        </group>
        <group group_id="B3">
          <title>Romosozumab 70 mg: 3 Doses</title>
          <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
        </group>
        <group group_id="B4">
          <title>Romosozumab 70 mg: 4 Doses</title>
          <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
        </group>
        <group group_id="B5">
          <title>Romosozumab 140 mg: 2 Doses</title>
          <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
        </group>
        <group group_id="B6">
          <title>Romosozumab 140 mg: 3 Doses</title>
          <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
        </group>
        <group group_id="B7">
          <title>Romosozumab 140 mg: 4 Doses</title>
          <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
        </group>
        <group group_id="B8">
          <title>Romosozumab 210 mg: 2 Doses</title>
          <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
        </group>
        <group group_id="B9">
          <title>Romosozumab 210 mg: 3 Doses</title>
          <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
        </group>
        <group group_id="B10">
          <title>Romosozumab 210 mg: 4 Doses</title>
          <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="103"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="34"/>
            <count group_id="B4" value="33"/>
            <count group_id="B5" value="33"/>
            <count group_id="B6" value="33"/>
            <count group_id="B7" value="33"/>
            <count group_id="B8" value="33"/>
            <count group_id="B9" value="31"/>
            <count group_id="B10" value="35"/>
            <count group_id="B11" value="402"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.3" spread="13.8"/>
                    <measurement group_id="B2" value="38.6" spread="13.8"/>
                    <measurement group_id="B3" value="43.2" spread="17.7"/>
                    <measurement group_id="B4" value="45.9" spread="15.6"/>
                    <measurement group_id="B5" value="41.3" spread="13.7"/>
                    <measurement group_id="B6" value="41.0" spread="14.9"/>
                    <measurement group_id="B7" value="38.7" spread="12.7"/>
                    <measurement group_id="B8" value="42.8" spread="13.7"/>
                    <measurement group_id="B9" value="36.8" spread="13.8"/>
                    <measurement group_id="B10" value="41.7" spread="14.4"/>
                    <measurement group_id="B11" value="40.9" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="13"/>
                    <measurement group_id="B10" value="12"/>
                    <measurement group_id="B11" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="22"/>
                    <measurement group_id="B8" value="28"/>
                    <measurement group_id="B9" value="18"/>
                    <measurement group_id="B10" value="23"/>
                    <measurement group_id="B11" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="25"/>
                    <measurement group_id="B9" value="24"/>
                    <measurement group_id="B10" value="28"/>
                    <measurement group_id="B11" value="299"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Randomization Stratification</title>
          <description>Randomization was stratified according to
Gustilo-Anderson System for classifying open tibial fractures:
Gustilo type I open fracture: Open tibial fracture with a puncture wound smaller than 1 cm.
Gustilo type II open fracture: Open tibial fracture with a wound of 1-10 cm.
Definitive fracture fixation: with reamed or unreamed intramedullary (IM) nailing.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Closed with reamed IM nail</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="29"/>
                    <measurement group_id="B8" value="29"/>
                    <measurement group_id="B9" value="28"/>
                    <measurement group_id="B10" value="29"/>
                    <measurement group_id="B11" value="350"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Gustilo type I/II open with reamed IM nail</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Gustilo type I/II open with unreamed IM nail</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Radiographic Healing</title>
        <description>Time to radiographic healing was defined as the time from intramedullary (IM) nailing to the first occurrence of bridging of 3 out of 4 cortices. Radiographic fracture healing was determined by a panel of independent reviewers (orthopedic/trauma surgeons and radiologists) blinded to treatment.
The cumulative incidence function (CIF) method was used to estimate the median time to radiographic healing and the confidence intervals. Unplanned revision surgery to promote healing was considered a competing risk in CIF estimate.</description>
        <time_frame>52 weeks</time_frame>
        <population>Participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received subcutaneous injections of matching placebo on day 1 and at weeks 2, 6, and 12.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 70 mg: 2 Doses</title>
            <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 70 mg: 3 Doses</title>
            <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 70 mg: 4 Doses</title>
            <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 140 mg: 2 Doses</title>
            <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 140 mg: 3 Doses</title>
            <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 140 mg: 4 Doses</title>
            <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
          </group>
          <group group_id="O8">
            <title>Romosozumab 210 mg: 2 Doses</title>
            <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 210 mg: 3 Doses</title>
            <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 210 mg: 4 Doses</title>
            <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Radiographic Healing</title>
          <description>Time to radiographic healing was defined as the time from intramedullary (IM) nailing to the first occurrence of bridging of 3 out of 4 cortices. Radiographic fracture healing was determined by a panel of independent reviewers (orthopedic/trauma surgeons and radiologists) blinded to treatment.
The cumulative incidence function (CIF) method was used to estimate the median time to radiographic healing and the confidence intervals. Unplanned revision surgery to promote healing was considered a competing risk in CIF estimate.</description>
          <population>Participants who received at least 1 dose of study drug.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="32"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="30"/>
                <count group_id="O10" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" lower_limit="14.6" upper_limit="18.0"/>
                    <measurement group_id="O2" value="18.6" lower_limit="14.0" upper_limit="24.4"/>
                    <measurement group_id="O3" value="18.3" lower_limit="13.0" upper_limit="21.0"/>
                    <measurement group_id="O4" value="18.2" lower_limit="13.7" upper_limit="20.7"/>
                    <measurement group_id="O5" value="17.8" lower_limit="12.6" upper_limit="22.9"/>
                    <measurement group_id="O6" value="18.1" lower_limit="13.1" upper_limit="20.7"/>
                    <measurement group_id="O7" value="17.0" lower_limit="12.7" upper_limit="21.4"/>
                    <measurement group_id="O8" value="14.4" lower_limit="12.6" upper_limit="17.0"/>
                    <measurement group_id="O9" value="15.4" lower_limit="13.3" upper_limit="17.4"/>
                    <measurement group_id="O10" value="16.4" lower_limit="14.4" upper_limit="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The cause-specific hazard was modeled using a Cox proportional hazards model with 10 treatment groups as the independent variable, stratified by type of fracture and definitive fracture fixation (closed with reamed IM nail, Gustilo type I/II open with reamed IM nail, Gustilo type I/II open with unreamed IM nail) and adjusting for quality of surgical fixation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3598</p_value>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
            <estimate_desc>A hazard ratio &gt; 1 favors romosozumab.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The cause-specific hazard was modeled using a Cox proportional hazards model with 10 treatment groups as the independent variable, stratified by type of fracture and definitive fracture fixation (closed with reamed IM nail, Gustilo type I/II open with reamed IM nail, Gustilo type I/II open with unreamed IM nail) and adjusting for quality of surgical fixation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6544</p_value>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
            <estimate_desc>A hazard ratio &gt; 1 favors romosozumab.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The cause-specific hazard was modeled using a Cox proportional hazards model with 10 treatment groups as the independent variable, stratified by type of fracture and definitive fracture fixation (closed with reamed IM nail, Gustilo type I/II open with reamed IM nail, Gustilo type I/II open with unreamed IM nail) and adjusting for quality of surgical fixation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9958</p_value>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
            <estimate_desc>A hazard ratio &gt; 1 favors romosozumab.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The cause-specific hazard was modeled using a Cox proportional hazards model with 10 treatment groups as the independent variable, stratified by type of fracture and definitive fracture fixation (closed with reamed IM nail, Gustilo type I/II open with reamed IM nail, Gustilo type I/II open with unreamed IM nail) and adjusting for quality of surgical fixation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6276</p_value>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
            <estimate_desc>A hazard ratio &gt; 1 favors romosozumab.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The cause-specific hazard was modeled using a Cox proportional hazards model with 10 treatment groups as the independent variable, stratified by type of fracture and definitive fracture fixation (closed with reamed IM nail, Gustilo type I/II open with reamed IM nail, Gustilo type I/II open with unreamed IM nail) and adjusting for quality of surgical fixation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8819</p_value>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
            <estimate_desc>A hazard ratio &gt; 1 favors romosozumab.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>The cause-specific hazard was modeled using a Cox proportional hazards model with 10 treatment groups as the independent variable, stratified by type of fracture and definitive fracture fixation (closed with reamed IM nail, Gustilo type I/II open with reamed IM nail, Gustilo type I/II open with unreamed IM nail) and adjusting for quality of surgical fixation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7197</p_value>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
            <estimate_desc>A hazard ratio &gt; 1 favors romosozumab.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>The cause-specific hazard was modeled using a Cox proportional hazards model with 10 treatment groups as the independent variable, stratified by type of fracture and definitive fracture fixation (closed with reamed IM nail, Gustilo type I/II open with reamed IM nail, Gustilo type I/II open with unreamed IM nail) and adjusting for quality of surgical fixation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6204</p_value>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.70</ci_upper_limit>
            <estimate_desc>A hazard ratio &gt; 1 favors romosozumab.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>The cause-specific hazard was modeled using a Cox proportional hazards model with 10 treatment groups as the independent variable, stratified by type of fracture and definitive fracture fixation (closed with reamed IM nail, Gustilo type I/II open with reamed IM nail, Gustilo type I/II open with unreamed IM nail) and adjusting for quality of surgical fixation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4779</p_value>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.84</ci_upper_limit>
            <estimate_desc>A hazard ratio &gt; 1 favors romosozumab.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>The cause-specific hazard was modeled using a Cox proportional hazards model with 10 treatment groups as the independent variable, stratified by type of fracture and definitive fracture fixation (closed with reamed IM nail, Gustilo type I/II open with reamed IM nail, Gustilo type I/II open with unreamed IM nail) and adjusting for quality of surgical fixation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9952</p_value>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
            <estimate_desc>A hazard ratio &gt; 1 favors romosozumab.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Week 8 in Short Form (36) Health Survey Physical Functioning Domain</title>
        <description>The Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2, is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical functioning domain includes 10 questions that assess limitations in physical activities because of health problems.
Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. The range of SF-36 physical functioning is 14.94 - 57.03. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement in physical functioning.</description>
        <time_frame>Week 8 and weeks 12, 16, 20, 24, 36, and 52</time_frame>
        <population>Participants who received at least 1 dose of study drug and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received subcutaneous injections of matching placebo on day 1 and at weeks 2, 6, and 12.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 70 mg: 2 Doses</title>
            <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 70 mg: 3 Doses</title>
            <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 70 mg: 4 Doses</title>
            <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 140 mg: 2 Doses</title>
            <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 140 mg: 3 Doses</title>
            <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 140 mg: 4 Doses</title>
            <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
          </group>
          <group group_id="O8">
            <title>Romosozumab 210 mg: 2 Doses</title>
            <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 210 mg: 3 Doses</title>
            <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 210 mg: 4 Doses</title>
            <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Week 8 in Short Form (36) Health Survey Physical Functioning Domain</title>
          <description>The Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2, is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical functioning domain includes 10 questions that assess limitations in physical activities because of health problems.
Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. The range of SF-36 physical functioning is 14.94 - 57.03. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement in physical functioning.</description>
          <population>Participants who received at least 1 dose of study drug and with available data at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="32"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="30"/>
                <count group_id="O10" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="28"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="29"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="27"/>
                    <count group_id="O9" value="27"/>
                    <count group_id="O10" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.77" spread="9.90"/>
                    <measurement group_id="O2" value="6.31" spread="6.84"/>
                    <measurement group_id="O3" value="5.67" spread="8.60"/>
                    <measurement group_id="O4" value="5.04" spread="9.01"/>
                    <measurement group_id="O5" value="4.28" spread="8.22"/>
                    <measurement group_id="O6" value="7.08" spread="8.06"/>
                    <measurement group_id="O7" value="3.63" spread="9.30"/>
                    <measurement group_id="O8" value="3.65" spread="9.06"/>
                    <measurement group_id="O9" value="7.33" spread="7.99"/>
                    <measurement group_id="O10" value="5.64" spread="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="29"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="28"/>
                    <count group_id="O9" value="25"/>
                    <count group_id="O10" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.64" spread="10.36"/>
                    <measurement group_id="O2" value="9.83" spread="7.24"/>
                    <measurement group_id="O3" value="9.19" spread="11.30"/>
                    <measurement group_id="O4" value="9.28" spread="11.14"/>
                    <measurement group_id="O5" value="8.89" spread="10.71"/>
                    <measurement group_id="O6" value="11.18" spread="9.23"/>
                    <measurement group_id="O7" value="8.78" spread="11.34"/>
                    <measurement group_id="O8" value="9.23" spread="9.59"/>
                    <measurement group_id="O9" value="9.50" spread="9.01"/>
                    <measurement group_id="O10" value="9.01" spread="10.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="27"/>
                    <count group_id="O7" value="22"/>
                    <count group_id="O8" value="25"/>
                    <count group_id="O9" value="24"/>
                    <count group_id="O10" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.20" spread="12.25"/>
                    <measurement group_id="O2" value="14.53" spread="9.69"/>
                    <measurement group_id="O3" value="10.45" spread="11.66"/>
                    <measurement group_id="O4" value="13.50" spread="12.02"/>
                    <measurement group_id="O5" value="12.13" spread="10.88"/>
                    <measurement group_id="O6" value="14.77" spread="13.52"/>
                    <measurement group_id="O7" value="12.44" spread="11.97"/>
                    <measurement group_id="O8" value="12.61" spread="10.88"/>
                    <measurement group_id="O9" value="12.50" spread="10.76"/>
                    <measurement group_id="O10" value="11.05" spread="11.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="25"/>
                    <count group_id="O9" value="24"/>
                    <count group_id="O10" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.87" spread="11.55"/>
                    <measurement group_id="O2" value="15.07" spread="9.31"/>
                    <measurement group_id="O3" value="10.34" spread="13.31"/>
                    <measurement group_id="O4" value="15.90" spread="11.26"/>
                    <measurement group_id="O5" value="14.57" spread="10.34"/>
                    <measurement group_id="O6" value="16.84" spread="12.70"/>
                    <measurement group_id="O7" value="11.79" spread="17.64"/>
                    <measurement group_id="O8" value="13.05" spread="10.99"/>
                    <measurement group_id="O9" value="13.05" spread="10.25"/>
                    <measurement group_id="O10" value="12.38" spread="14.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="26"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="26"/>
                    <count group_id="O10" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.57" spread="11.60"/>
                    <measurement group_id="O2" value="20.96" spread="11.68"/>
                    <measurement group_id="O3" value="11.48" spread="17.84"/>
                    <measurement group_id="O4" value="17.23" spread="10.15"/>
                    <measurement group_id="O5" value="17.61" spread="11.03"/>
                    <measurement group_id="O6" value="19.43" spread="12.83"/>
                    <measurement group_id="O7" value="15.70" spread="19.03"/>
                    <measurement group_id="O8" value="15.01" spread="11.23"/>
                    <measurement group_id="O9" value="17.47" spread="14.34"/>
                    <measurement group_id="O10" value="15.22" spread="15.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="26"/>
                    <count group_id="O10" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.74" spread="11.96"/>
                    <measurement group_id="O2" value="23.47" spread="11.55"/>
                    <measurement group_id="O3" value="13.63" spread="19.04"/>
                    <measurement group_id="O4" value="19.02" spread="10.80"/>
                    <measurement group_id="O5" value="19.63" spread="12.17"/>
                    <measurement group_id="O6" value="24.80" spread="11.24"/>
                    <measurement group_id="O7" value="17.19" spread="15.51"/>
                    <measurement group_id="O8" value="15.50" spread="13.17"/>
                    <measurement group_id="O9" value="18.29" spread="14.94"/>
                    <measurement group_id="O10" value="15.44" spread="17.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Unplanned Revision Surgeries</title>
        <time_frame>52 weeks</time_frame>
        <population>Participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received subcutaneous injections of matching placebo on day 1 and at weeks 2, 6, and 12.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 70 mg: 2 Doses</title>
            <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 70 mg: 3 Doses</title>
            <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 70 mg: 4 Doses</title>
            <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 140 mg: 2 Doses</title>
            <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 140 mg: 3 Doses</title>
            <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 140 mg: 4 Doses</title>
            <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
          </group>
          <group group_id="O8">
            <title>Romosozumab 210 mg: 2 Doses</title>
            <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 210 mg: 3 Doses</title>
            <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 210 mg: 4 Doses</title>
            <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unplanned Revision Surgeries</title>
          <population>Participants who received at least 1 dose of study drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="32"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="30"/>
                <count group_id="O10" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Clinical Healing</title>
        <description>Time to clinical healing was defined as the time from the IM nailing surgery date to the first date that both the score for ability to bear weight on the fractured limb and the score for absence of pain at the fracture site were equal to 6.
The score for the ability to bear weight on the fractured limb was based on the ability to stand on affected leg without assistive device and the ability to walk without assistive device. The score ranges from 0 (unable to bear full body weight on the fractured limb) to 6 (able to bear full body weight on the fractured limb). Absence of pain at the fracture site was based on the absence of pain at the fracture site when applying direct pressure to the fracture site and applying a stress to the fracture site. The score ranges from 0 (pain without palpation at fracture site) to 6 (total absence of pain at fracture site).
Time to clinical healing was estimated using CIF; unplanned revision surgery was considered a competing risk in CIF estimate.</description>
        <time_frame>52 weeks</time_frame>
        <population>Participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received subcutaneous injections of matching placebo on day 1 and at weeks 2, 6, and 12.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 70 mg: 2 Doses</title>
            <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 70 mg: 3 Doses</title>
            <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 70 mg: 4 Doses</title>
            <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 140 mg: 2 Doses</title>
            <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 140 mg: 3 Doses</title>
            <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 140 mg: 4 Doses</title>
            <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
          </group>
          <group group_id="O8">
            <title>Romosozumab 210 mg: 2 Doses</title>
            <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 210 mg: 3 Doses</title>
            <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 210 mg: 4 Doses</title>
            <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Clinical Healing</title>
          <description>Time to clinical healing was defined as the time from the IM nailing surgery date to the first date that both the score for ability to bear weight on the fractured limb and the score for absence of pain at the fracture site were equal to 6.
The score for the ability to bear weight on the fractured limb was based on the ability to stand on affected leg without assistive device and the ability to walk without assistive device. The score ranges from 0 (unable to bear full body weight on the fractured limb) to 6 (able to bear full body weight on the fractured limb). Absence of pain at the fracture site was based on the absence of pain at the fracture site when applying direct pressure to the fracture site and applying a stress to the fracture site. The score ranges from 0 (pain without palpation at fracture site) to 6 (total absence of pain at fracture site).
Time to clinical healing was estimated using CIF; unplanned revision surgery was considered a competing risk in CIF estimate.</description>
          <population>Participants who received at least 1 dose of study drug</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="32"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="30"/>
                <count group_id="O10" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" lower_limit="16.6" upper_limit="20.4"/>
                    <measurement group_id="O2" value="21.4" lower_limit="15.7" upper_limit="28.6"/>
                    <measurement group_id="O3" value="18.3" lower_limit="14.4" upper_limit="22.4"/>
                    <measurement group_id="O4" value="17.1" lower_limit="14.4" upper_limit="21.0"/>
                    <measurement group_id="O5" value="20.8" lower_limit="12.6" upper_limit="28.0"/>
                    <measurement group_id="O6" value="22.3" lower_limit="15.0" upper_limit="24.3"/>
                    <measurement group_id="O7" value="15.0" lower_limit="12.6" upper_limit="17.0"/>
                    <measurement group_id="O8" value="16.3" lower_limit="12.4" upper_limit="21.0"/>
                    <measurement group_id="O9" value="14.6" lower_limit="12.9" upper_limit="18.6"/>
                    <measurement group_id="O10" value="17.6" lower_limit="14.9" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The cause-specific hazard was modeled using a Cox proportional hazards model with 10 treatment groups as the independent variable, stratified by type of fracture and definitive fracture fixation (closed with reamed IM nail, Gustilo type I/II open with reamed IM nail, Gustilo type I/II open with unreamed IM nail) and adjusting for quality of surgical fixation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1713</p_value>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>A hazard ratio &gt; 1 favors romosozumab.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The cause-specific hazard was modeled using a Cox proportional hazards model with 10 treatment groups as the independent variable, stratified by type of fracture and definitive fracture fixation (closed with reamed IM nail, Gustilo type I/II open with reamed IM nail, Gustilo type I/II open with unreamed IM nail) and adjusting for quality of surgical fixation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9958</p_value>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
            <estimate_desc>A hazard ratio &gt; 1 favors romosozumab.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The cause-specific hazard was modeled using a Cox proportional hazards model with 10 treatment groups as the independent variable, stratified by type of fracture and definitive fracture fixation (closed with reamed IM nail, Gustilo type I/II open with reamed IM nail, Gustilo type I/II open with unreamed IM nail) and adjusting for quality of surgical fixation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2950</p_value>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.97</ci_upper_limit>
            <estimate_desc>A hazard ratio &gt; 1 favors romosozumab.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The cause-specific hazard was modeled using a Cox proportional hazards model with 10 treatment groups as the independent variable, stratified by type of fracture and definitive fracture fixation (closed with reamed IM nail, Gustilo type I/II open with reamed IM nail, Gustilo type I/II open with unreamed IM nail) and adjusting for quality of surgical fixation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0844</p_value>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>A hazard ratio &gt; 1 favors romosozumab.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The cause-specific hazard was modeled using a Cox proportional hazards model with 10 treatment groups as the independent variable, stratified by type of fracture and definitive fracture fixation (closed with reamed IM nail, Gustilo type I/II open with reamed IM nail, Gustilo type I/II open with unreamed IM nail) and adjusting for quality of surgical fixation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3225</p_value>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
            <estimate_desc>A hazard ratio &gt; 1 favors romosozumab.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>The cause-specific hazard was modeled using a Cox proportional hazards model with 10 treatment groups as the independent variable, stratified by type of fracture and definitive fracture fixation (closed with reamed IM nail, Gustilo type I/II open with reamed IM nail, Gustilo type I/II open with unreamed IM nail) and adjusting for quality of surgical fixation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4754</p_value>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
            <estimate_desc>A hazard ratio &gt; 1 favors romosozumab.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>The cause-specific hazard was modeled using a Cox proportional hazards model with 10 treatment groups as the independent variable, stratified by type of fracture and definitive fracture fixation (closed with reamed IM nail, Gustilo type I/II open with reamed IM nail, Gustilo type I/II open with unreamed IM nail) and adjusting for quality of surgical fixation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5578</p_value>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
            <estimate_desc>A hazard ratio &gt; 1 favors romosozumab.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>The cause-specific hazard was modeled using a Cox proportional hazards model with 10 treatment groups as the independent variable, stratified by type of fracture and definitive fracture fixation (closed with reamed IM nail, Gustilo type I/II open with reamed IM nail, Gustilo type I/II open with unreamed IM nail) and adjusting for quality of surgical fixation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1864</p_value>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>2.07</ci_upper_limit>
            <estimate_desc>A hazard ratio &gt; 1 favors romosozumab</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>The cause-specific hazard was modeled using a Cox proportional hazards model with 10 treatment groups as the independent variable, stratified by type of fracture and definitive fracture fixation (closed with reamed IM nail, Gustilo type I/II open with reamed IM nail, Gustilo type I/II open with unreamed IM nail) and adjusting for quality of surgical fixation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8488</p_value>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
            <estimate_desc>A hazard ratio &gt; 1 favors romosozumab.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks</time_frame>
      <desc>Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received subcutaneous injections of matching placebo on day 1 and at weeks 2, 6, and 12.</description>
        </group>
        <group group_id="E2">
          <title>Romosozumab 70 mg: 2 Doses</title>
          <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
        </group>
        <group group_id="E3">
          <title>Romosozumab 70 mg: 3 Doses</title>
          <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
        </group>
        <group group_id="E4">
          <title>Romosozumab 70 mg: 4 Doses</title>
          <description>Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
        </group>
        <group group_id="E5">
          <title>Romosozumab 140 mg: 2 Doses</title>
          <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12</description>
        </group>
        <group group_id="E6">
          <title>Romosozumab 140 mg: 3 Doses</title>
          <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12</description>
        </group>
        <group group_id="E7">
          <title>Romosozumab 140 mg: 4 Doses</title>
          <description>Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
        </group>
        <group group_id="E8">
          <title>Romosozumab 210 mg: 2 Doses</title>
          <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.</description>
        </group>
        <group group_id="E9">
          <title>Romosozumab 210 mg: 3 Doses</title>
          <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.</description>
        </group>
        <group group_id="E10">
          <title>Romosozumab 210 mg: 4 Doses</title>
          <description>Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2, 6, and 12.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bone fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Loss of anatomical alignment after fracture reduction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Medical device removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Medical device discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
      <email>medinfo@amgen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

